Sociodemographic characteristics and cardiovascular risk factors in patients with severe mental disorders compared with the general population

Journal of Clinical Psychiatry

Volumn 67, Issue 3, 2006, Pages 425-433

  Birkenaes, Astrid B ^a   Søgaard, Anne J ^b   Engh, John A ^a   Jonsdottir, Halldora ^a   Ringen, P Andreas ^a   Vaskinn, Anja ^a   Friis, Svein ^a   Sundet, Kjetil ^b   Opjordsmoen, Stein ^a   Andreassen, Ole A ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES MELLITUS; DYSLIPIDEMIA; ETHNIC GROUP; FEMALE; GENDER AND SEX; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MARRIAGE; MENTAL DISEASE; METABOLIC SYNDROME X; OBESITY; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; RISK ASSESSMENT; SMOKING; SOCIAL BACKGROUND; SOCIOECONOMICS;

EID: 33645779997     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v67n0314     Document Type: Article

References (30)

1. Hu G, Qiao Q, Tuomilehto J, et al. for the DECODE Study Group. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 2004;164:1066-1076
2. Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004;161:1334-1349
3. Brown S. Excess mortality of schizophrenia: a meta-analysis. Br J Psychiatry 1997;171:502-508
4. Osby U, Correia N, Brandt L, et al. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res 2000;45:21-28
5. Osby U, Brandt L, Correia N, et al. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry 2001;58:844-850
6. Davidson S, Judd F, Jolley D, et al. Cardiovascular risk factors for people with mental illness. Aust N Z J Psychiatry 2001;35:196-202
7. Ryan MC, Thakore JH. Physical consequences of schizophrenia and its treatment: the metabolic syndrome. Life Sci 2002;71:239-257
8. Heiskanen T, Niskanen L, Lyytikainen R, et al. Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry 2003;64:575-579
9. Basu R, Brar JS, Chengappa KNR, et al. The prevalence of the metabolic syndrome in patients with schizoaffective disorder-bipolar subtype. Bipolar Disord 2004;6:314-318
10. Conn T, Prud'homme D, Streiner D, et al. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry 2004;49:753-760
11. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005;80:19-32
12. Kupfer DJ. The increasing medical burden in bipolar disorder. JAMA 2005;293:2528-2530
13. Bell CG, Walley AJ, Froguel P. The genetics of human obesity. Nat Rev Genet 2005;6:221-234
14. Strand BH, Tverdal A. Can cardiovascular risk factors and lifestyle explain the educational inequalities in mortality from ischaemic heart disease and from other heart diseases? 26 year follow up of 50 000 Norwegian men and women. J Epidemiol Community Health 2004;58:705-709
15. Allison DB, Fontaine KR, Heo M, et al. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry 1999;60:215-220
16. Koro CE, Fedder DO, L'Italien GJ, et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ 2002;325:243
17. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156: 1686-1696
18. Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 2004;70:1-17
19. Nasrallah HA, Newcomer JW. Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care. J Clin Psychopharmacol 2004;24:S7-S14
20. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596-601
21. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223
22. Balkau B, Charles M-A, for the European Group for the Study of Insulin Resistance (EGIR). Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab 2002;28:364-376
23. Homel P, Casey D, Allison DB. Changes in body mass index for individuals with and without schizophrenia, 1987-1996. Schizophr Res 2002;55:277-284
24. Chaturvedi N. Ethnic differences in cardiovascular disease. Heart 2003;89:681-686
25. Søgaard AJ, Selmer R. The Oslo Health Study. Norwegian Institute of Public Health (Nasjonalt Folkehelseinstitutt). Available at: http://www.fhi.no/dav/A4BEAA46FC.doc. Accessibility verified January 17, 2006
26. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications, pt 1: diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation. Diabet Med 1998;15:539-553
27. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. INTERHEART Study Investigators. Lancet 2004;364:937-952
28. Expert Panel of Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497
29. Søgaard AJ, Selmer R, Bjertness E, et al. The Oslo Health Study: the impact of self-selection in a large, population-based survey. Int J Equity Health 2004;3:3
30. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA 2002;287:356-359